Biogen Inc.

NasdaqGS:BIIB Aktierapport

Börsvärde: US$32.0b

Biogen Framtida tillväxt

Future kriterier kontrolleras 1/6

Biogen förväntas öka intäkter och intäkter med 14.2% respektive 2.5% per år. EPS förväntas tillväxt med 14.4% per år. Avkastningen på eget kapital förväntas bli 12.7% om 3 år.

Viktig information

14.2%

Tillväxttakt i vinsten

14.36%

Tillväxttakt för EPS

Biotechs vinsttillväxt25.2%
Intäkternas tillväxttakt2.5%
Framtida avkastning på eget kapital12.74%
Bevakning av analytiker

Good

Senast uppdaterad29 Jun 2026

Senaste uppdateringarna om framtida tillväxt

Recent updates

Uppdatering av berättelse • Jun 24

BIIB: Late Stage Neurology Readouts And Immunology Deals Will Drive Upside

Biogen's analyst price target edges higher, with a modest fair value move from about $279.24 to $279.94 as analysts factor in recent upgrades, revised models around the Apellis acquisition, and upcoming Alzheimer's data readouts such as diranersen at AAIC. Analyst Commentary Recent Street research on Biogen points to a cluster of constructive views around the Apellis acquisition, the Alzheimer’s franchise, and a broader late stage pipeline.
Uppdatering av berättelse • Jun 09

BIIB: Late Stage Neurology And Immunology Pipeline Will Drive Future Upside

Analysts have nudged their Biogen fair value estimate higher by about $6 to roughly $279, citing a combination of pipeline updates, a steadier core business and revised expectations for margins, growth and future P/E multiples as reflected in recent price target changes across the Street. Analyst Commentary Recent research points to a clear shift toward more constructive views on Biogen, with several bullish analysts lifting price targets and upgrading ratings as they reassess the pipeline and core franchises.
Uppdatering av berättelse • May 26

BIIB: Tau Alzheimer’s Data And EPS Upside Will Drive Future Upside

Biogen's updated analyst price target has shifted from about $206 to $219, as analysts weigh mixed but encouraging tau program data, potential EPS upside, and a modestly higher assumed future P/E multiple. Analyst Commentary Recent research views on Biogen cluster around mixed tau data, potential earnings power, and how much of that is already reflected in the stock's valuation.
Uppdatering av berättelse • May 04

BIIB: 2026 Readouts In Neurology And Immunology Will Drive Upside Potential

Analysts have lifted Biogen's fair value estimate by about $18 to $273.20 as they factor in updated revenue growth assumptions, a higher future P/E, and recent price target revisions across the Street. Analyst Commentary Recent Street research around Biogen has leaned constructive, with a cluster of fresh price target adjustments and several rating upgrades pointing to improving sentiment on execution and long term growth potential.
Uppdatering av berättelse • Apr 20

BIIB: 2026 Trial Outcomes Will Likely Undermine Recent Acquisition Optimism

Analysts made a slight upward adjustment to Biogen's fair value estimate to about $151, reflecting a blend of higher and lower price target revisions related to recent acquisition activity, pipeline updates, and shifting views on its long term earnings profile. Analyst Commentary Recent Street research around Biogen has been active, with a mix of higher and lower price targets clustered around the company’s acquisition activity, pipeline readouts, and changing expectations for longer term earnings power.
Seeking Alpha • Apr 06

Revisiting Eisai And Biogen's Leqembi Data For Alzheimer's Disease

Summary Eisai (ESALF) and Biogen (BIIB) have presented inconsistent efficacy claims for Leqembi in Alzheimer's, particularly regarding APOE4 genetic subgroups. Real-world data may reveal Leqembi is only marginally effective for APOE4 single-copy carriers, with little benefit for non-carriers or double-copy carriers. BIIB may be more resilient than ESALF to negative Leqembi developments due to pipeline diversity, but no near-term catalysts are evident for BIIB stock movement. Efforts to expand Leqembi’s market may be misguided; regulatory scrutiny and emerging alternatives could further limit its commercial potential. Read the full article on Seeking Alpha
Uppdatering av berättelse • Apr 05

BIIB: 2026 Clinical Outcomes Will Likely Challenge Recent Neuroscience Optimism

The analyst price target for Biogen has been adjusted slightly to $150. This reflects recent model updates that incorporate a modestly higher discount rate, slightly lower revenue growth assumptions, a small uptick in expected profit margins, and Street research focusing on price target changes and evolving views on the company's pipeline and neurology portfolio.
Uppdatering av berättelse • Mar 22

BIIB: 2026 Clinical Readouts Will Likely Undermine Recent Pipeline Optimism

Analysts have nudged Biogen's fair value estimate higher to $151.48 from $147.47, reflecting a series of recent price target increases across the Street and ongoing reassessments of the company's pipeline and commercial outlook. Analyst Commentary Recent Street research around Biogen points to a mixed setup, with several firms adjusting price targets and ratings as they reassess the pipeline, commercial execution, and sector positioning.
Uppdatering av berättelse • Mar 07

BIIB: 2026 Clinical Readouts And Easing Policy Risks Will Drive Upside

The analyst fair value estimate for Biogen has increased by about $16 to $205.67 as analysts factor in recent price target revisions and updated views on the pipeline and commercial outlook. Analyst Commentary Recent research updates on Biogen cluster around revisions to price targets, refreshed models on the pipeline, and differing expectations for execution in 2026 and beyond.
Uppdatering av berättelse • Feb 21

BIIB: 2026 Clinical Readouts Will Likely Expose Pipeline Execution Risk

The analyst price target for Biogen has been raised from $143.00 to $147.47. Analysts point to a stronger profit margin outlook and updated pipeline and commercial assumptions as key drivers of the change.
Analysartikel • Feb 13

There May Be Reason For Hope In Biogen's (NASDAQ:BIIB) Disappointing Earnings

Shareholders appeared unconcerned with Biogen Inc.'s ( NASDAQ:BIIB ) lackluster earnings report last week. We think...
Uppdatering av berättelse • Feb 07

BIIB: 2026 Clinical Readouts And Pipeline Execution Will Drive Upside Potential

Analysts have nudged their price targets on Biogen higher, with our fair value estimate rising to about $255.45 from $247.88 as they update models for revenue growth, margins, and a modestly richer future P/E multiple following a series of mixed but generally upward target revisions across the Street. Analyst Commentary Recent research on Biogen has been mixed, but the pricing and modeling changes skew toward a constructive tone.
Uppdatering av berättelse • Jan 23

BIIB: 2026 Clinical Readouts Will Test Lofty Pipeline Expectations

Analysts have raised their Biogen fair value estimate from $128.00 to $143.00, citing refreshed models and higher Street price targets as they incorporate updated views on the pipeline, sector conditions, and 2026 catalysts. Analyst Commentary Street research around Biogen points to a generally more constructive view on the shares, with several firms lifting price targets into a range between about $180 and $225.
Uppdatering av berättelse • Jan 09

BIIB: Easing Policy Shifts And 2026 Pipeline Readouts Will Shape Outlook

Narrative Update: Biogen (BIIB) Biogen's fair value estimate has moved from about $181 to around $190 as analysts lift price targets into the $180 to $225 range and highlight updated models, slightly better margin and growth assumptions, and potential pipeline and sector catalysts through 2026. Analyst Commentary Recent research updates on Biogen cluster around a tighter valuation band in the high US$100s to low US$200s, with most firms revisiting their models and assumptions for 2025 to 2026.
Uppdatering av berättelse • Dec 24

BIIB: Easing Policy Overhangs And Alzheimer’s Data Will Shape Risk Reward Balance

Analysts have modestly raised their price target on Biogen, now implying upside in line with a slightly higher fair value of approximately $181, citing easing policy overhangs and a partial rerating of large-cap biopharma as investor focus shifts back to fundamentals. Analyst Commentary Street research on Biogen has turned incrementally more constructive, with several firms lifting price targets as macro and policy risks appear less threatening to the sector.
Uppdatering av berättelse • Dec 10

BIIB: Policy Environment And Late-Stage Pipeline Will Shape Risk And Reward Ahead

Analysts have modestly increased their price target for Biogen, lifting fair value by about $1 to roughly $179 per share. They cite easing policy overhangs, growing confidence in 2025 to 2026 fundamentals, and potential upside from Leqembi and the broader late stage pipeline.
Uppdatering av berättelse • Nov 26

BIIB: Policy Shifts And Drug Pipeline Progress Will Influence Risk And Reward Ahead

Biogen's analyst price target has been increased modestly, with the fair value estimate rising from $176.72 to $178.07. Analysts point to easing policy headwinds and renewed focus on company fundamentals amid recent sector re-ratings.
Uppdatering av berättelse • Nov 12

BIIB: Pipeline And Policy Developments Will Shape Risk And Reward Into 2025

Analysts have raised their price target for Biogen by approximately $4 to $176.72, citing improving sector fundamentals, easing policy risks, and a favorable risk/reward outlook as reasons for the adjustment. Analyst Commentary Recent street research on Biogen provides insight into both the optimistic and cautious perspectives that currently shape the stock's outlook.
Uppdatering av berättelse • Oct 29

Easing Policy Risks And New Therapy Launches Will Drive Shares Higher

Analysts have slightly raised their price target for Biogen to $172.55 from $172.34, reflecting modestly improved revenue growth expectations and an easing policy backdrop in the biotech sector. Analyst Commentary Recent street research reveals a spectrum of opinions around Biogen, highlighted by both bullish and bearish analyst actions.
Uppdatering av berättelse • Oct 15

Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth

Analysts have slightly lifted their price targets for Biogen, with the updated fair value estimate rising from $170.03 to $172.34. This reflects improved profit margin expectations and easing industry headwinds cited in recent research updates.
Uppdatering av berättelse • Sep 20

Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth

Biogen's modestly reduced consensus price target reflects a balanced analyst view, with optimism around strong Q2 performance, pipeline progress, and portfolio refocusing offset by lingering regulatory overhangs and a muted near-term growth outlook, resulting in a slight decrease in fair value from $171.96 to $170.03. Analyst Commentary Bullish analysts cite strong Q2 performance, particularly from Leqembi and the MS franchise, as well as solid sales across other programs as drivers for raised price targets.
Uppdatering av berättelse • Sep 05

Expanding Global Healthcare And Diagnostics Infrastructure Will Drive Future Growth

Biogen’s consensus price target was modestly raised as analysts highlighted strong Q2 performance, advancements in its neuro portfolio and pipeline, and ongoing portfolio refocusing, offsetting medium-term growth concerns and regulatory risks; the new fair value is now $171.96. Analyst Commentary Bullish analysts highlight strong Q2 performance, particularly in Leqembi and the MS franchise, combined with solid sales across other programs, supporting upward revisions in price targets.
Seeking Alpha • Apr 25

Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent?

Summary Biogen Inc.'s earnings and share price have declined due to falling Multiple Sclerosis treatment revenue; new drugs and pipeline show promise but haven't offset losses yet. Biogen's Multiple Sclerosis treatments face patent expirations and competition, pressuring revenue; new Alzheimer's Disease and rare disease treatments could drive future growth. Financially, Biogen remains profitable with strong FCF, but reduced R&D spending and lack of insider buying or share buybacks are concerning. I rate BIIB stock a hold due to current uncertainties; will reconsider upon sustained revenue growth, regulatory approvals, or positive trial data. Read the full article on Seeking Alpha

Prognoser för vinst- och omsättningstillväxt

NasdaqGS:BIIB - Analytikernas framtida uppskattningar och tidigare finansiella data (USD Millions )
DatumIntäkterIntäkterFritt kassaflödeKassaflöde från rörelsenGenomsnittligt Antal analytiker
12/31/202810,6822,2132,4113,47618
12/31/202710,3811,9692,6072,61723
12/31/202610,0531,1772,6691,76523
3/31/20269,9371,3722,3162,591N/A
12/31/20259,8911,2931,9692,205N/A
9/30/202510,0661,6092,2622,454N/A
6/30/20259,9971,5311,8322,117N/A
3/31/20259,8161,4792,3842,582N/A
12/31/20249,6761,6322,6042,876N/A
9/30/20249,6081,6151,8572,127N/A
6/30/20249,6721,1591,5711,784N/A
3/31/20249,6631,1671,2841,645N/A
12/31/20239,8361,1611,2361,547N/A
9/30/20239,9931,4621,0261,360N/A
6/30/20239,9722,6651,1231,428N/A
3/31/202310,1053,1311,4211,678N/A
12/31/202210,1733,0471,1411,384N/A
9/30/202210,3632,8652,1732,398N/A
6/30/202210,6342,0592,3152,542N/A
3/31/202210,8201,4502,7733,033N/A
12/31/202110,9821,5563,3453,640N/A
9/30/202111,1011,5462,1072,435N/A
6/30/202111,6981,9182,4612,810N/A
3/31/202112,6043,0123,1493,532N/A
12/31/202013,4454,0013,6784,230N/A
9/30/202014,2635,0825,8416,557N/A
6/30/202014,4875,9276,3497,071N/A
3/31/202014,4225,8796,2827,086N/A
12/31/201914,3785,889N/A7,079N/A
9/30/201914,2335,396N/A7,014N/A
6/30/201914,0725,294N/A7,055N/A
3/31/201913,8124,667N/A6,190N/A
12/31/201813,4534,431N/A6,188N/A
9/30/201813,2343,187N/A5,811N/A
6/30/201812,8722,968N/A5,703N/A
3/31/201812,5942,964N/A5,773N/A
12/31/201712,2742,539N/A4,551N/A
9/30/201711,8393,486N/A4,615N/A
6/30/201711,7173,293N/A3,978N/A
3/31/201711,5333,480N/A3,807N/A
12/31/201611,4493,703N/A4,587N/A
9/30/201611,4163,885N/A4,046N/A
6/30/201611,2383,818N/A3,950N/A
3/31/201610,9363,695N/A3,999N/A
12/31/201510,7643,547N/A3,919N/A
9/30/201510,5653,599N/A3,609N/A

Analytiker Framtid Tillväxt Prognoser

Intäkter kontra sparande: BIIB s prognostiserade vinsttillväxt ( 14.2% per år) är över sparkvoten ( 3.5% ).

Resultat vs marknad: BIIB s intäkter ( 14.2% per år) förväntas växa långsammare än marknaden för US ( 18.6% per år).

Höga tillväxtresultat: BIIB s intäkter förväntas växa, men inte avsevärt.

Intäkt vs marknad: BIIB s intäkter ( 2.5% per år) förväntas växa långsammare än marknaden för US ( 12.7% per år).

Hög tillväxtintäkter: BIIB s intäkter ( 2.5% per år) förväntas växa långsammare än 20% per år.

Tillväxtprognoser för vinst per aktie

Framtida avkastning på eget kapital

Framtida ROE: BIIB s avkastning på eget kapital förväntas bli låg om 3 år ( 12.7 %).

Upptäck tillväxtföretag

7D

1Y

7D

1Y

7D

1Y

Företagsanalys och finansiella data Status

UppgifterSenast uppdaterad (UTC-tid)
Analys av företag2026/06/30 09:42
Aktiekurs vid dagens slut2026/06/29 00:00
Intäkter2026/03/31
Årlig intjäning2025/12/31

Datakällor

Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.

PaketUppgifterTidsramExempel US-källa
Företagets finansiella ställning10 år
  • Resultaträkning
  • Kassaflödesanalys
  • Balansräkning
Analytikernas konsensusuppskattningar+3 år
  • Prognos för finansiella poster
  • Analytikernas prismål
Marknadspriser30 år
  • Aktiekurser
  • Utdelningar, splittar och åtgärder
Ägarskap10 år
  • Största aktieägare
  • Insiderhandel
Förvaltning10 år
  • Ledningsgrupp
  • Styrelse och verkställande direktörer
Viktiga utvecklingstendenser10 år
  • Företagsmeddelanden

* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.

Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.

Analysmodell och snöflinga

Detaljer om analysmodellen som används för att skapa denna rapport finns på vår Github-sida; vi har också guider om hur du använder våra rapporter och handledningar på Youtube.

Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.

Industri- och sektormått

Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.

Källor för analytiker

Biogen Inc. bevakas av 58 analytiker. 23 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.

AnalytikerInstitution
David ToungArgus Research Company
Brian SkorneyBaird
Emily FieldBarclays